US20070088077A1 - Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection - Google Patents
Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection Download PDFInfo
- Publication number
- US20070088077A1 US20070088077A1 US11/537,914 US53791406A US2007088077A1 US 20070088077 A1 US20070088077 A1 US 20070088077A1 US 53791406 A US53791406 A US 53791406A US 2007088077 A1 US2007088077 A1 US 2007088077A1
- Authority
- US
- United States
- Prior art keywords
- patient
- delta
- tetrahydrocannabinol
- human patient
- hiv infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000031886 HIV Infections Diseases 0.000 title claims abstract description 11
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract description 11
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract description 11
- 208000016261 weight loss Diseases 0.000 title description 8
- 230000004580 weight loss Effects 0.000 title description 8
- 230000007943 positive regulation of appetite Effects 0.000 title 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 35
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims abstract description 33
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 230000004584 weight gain Effects 0.000 claims description 7
- 235000019786 weight gain Nutrition 0.000 claims description 7
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 229960004242 dronabinol Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- 229960002555 zidovudine Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 17
- 206010028813 Nausea Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000036528 appetite Effects 0.000 abstract description 7
- 235000019789 appetite Nutrition 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 5
- 208000030507 AIDS Diseases 0.000 abstract description 3
- 208000020442 loss of weight Diseases 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 6
- 229960003111 prochlorperazine Drugs 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000000816 Intravenous Substance Abuse Diseases 0.000 description 1
- WHKUVVPPKQRRBV-UHFFFAOYSA-N Trasan Chemical compound CC1=CC(Cl)=CC=C1OCC(O)=O WHKUVVPPKQRRBV-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 244000261228 chanvre indien Species 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Definitions
- HIV infection includes inter alia AIDS (Acquired Immune Deficiency Syndrome) and ARC (AIDS Related Complex), are loss of appetite with consequent loss of weight. This loss of appetite and loss of weight further debilitates the patients and increases the many problems associated with the HIV infection.
- AIDS Abnormal Immune Deficiency Syndrome
- ARC AIDS Related Complex
- the compound delta-9-tetrahydrocannabinol which is the active ingredient in marijuana and which was produced chemically as described in U.S. Pat. No. 3,668,224, has been used as an antiemetic to relieve nausea and vomiting in patients receiving cancer chemotherapy.
- delta-9-tetrahydrocannabinol A number of cancer investigators have used delta-9-tetrahydrocannabinol to attempt to increase appetite and modify weight loss in cancer patients. For example, in a randomized double-blind crossover study employing oral delta-9-tetrahydrocannabinol and prochlorperazine, 50% of the subjects on delta-9-tetrahydrocannabinol reported an increased food intake while only 29% had a similar response on the prochlorperazine. 1 In another study of similar design and using the same medications, patients on delta-9-tetrahydrocannabinol reported feeling more hungry than patients on prochlorperazine. 2 Results suggestive of an appetite stimulating effect were also noted by Ekert, et al.
- Wadleigh, et al. 5 observed appetite increases and a lessening of the rate of weight loss in cancer patients. 5 Wadleigh, R; Spaulding, M; Lembersky, B; Zimmer. M: Shepard, K; Plasse, T; Dronabinol enhancement of appetite in cancer patients. Proceedings 1990 American Cancer Society of Clinical Mycology Meeting.
- the present invention mainly comprises the administration to a patient suffering from symptomatic HIV infection of an appetite stimulating effective amount of delta-9-tetrahydrocannabinol.
- the delta-9-tetrahydrocannabinol is preferably administered orally as dronabinol (delta-9-tetrahydrocannabinol in sesame oil-containing capsules). Administration is also possible to achieve the effects of the present invention when the delta-9-tetrahydrocannabinol is in the form of tablets, suppositories, intranasal administration, transdermal administration, inhalants and sublingual administration, as well as administration by injection.
- delta-9-tetrahydrocannabinol may vary widely from 2.5 mg to 20 mg daily, in single or divided doses.
- Soft gelatin capsules were filled with delta-9-tetrahydrocannabinol in sesame oil (dronabinol).
- Capsules were filled with 2.5 mg delta-9-tetrahydrocannabinol per capsule or 5 mg delta-9-tetrahydrocannabinol per capsule.
- Example I At a dose which appears optimal, seven of eight patients completed one month treatment. At that dose, most patients did not experience side effects. Most of those patients who did experience side effects found them tolerable. Confirming the unexpected results of Example I, five of the seven patients gained weight.
- the median rate of weight loss prior to therapy was 1.62 kg/mo; on therapy, the median weight gain was 1.56 kg/mo.
- the median improvement in the rate of weight change was 3.06 kg/mo, or approximately 1.5 lbs/wk.
- delta-9-tetrahydrocannabinol can provide a significant tool in the treatment of patients with symptomatic HIV infection by improving appetite and reducing weight loss.
Abstract
Patients with symptomatic HIV infection, including AIDS and ARC are treated to increase appetite and to cause a reduction in loss of weight. The delta-9-tetrahydrocannabinol may be administered orally, in capsules, or in tablets, or by injection, suppository, intranasal, transdermal, inhalant or sublingual administration.
Description
- This application is a continuation of and claims priority to U.S. application Ser. No. 10/735,017, filed Dec. 12, 2003, which is a continuation of U.S. application Ser. No. 07/893,554, filed Jun. 3, 1992, which is a continuation of U.S. application Ser. No. 07/661,514, filed Feb. 26, 1991, all of which are incorporated herein by reference in their entirety to the extent permitted by law.
- Among the many problems endured by patients suffering from symptomatic HIV infection, which includes inter alia AIDS (Acquired Immune Deficiency Syndrome) and ARC (AIDS Related Complex), are loss of appetite with consequent loss of weight. This loss of appetite and loss of weight further debilitates the patients and increases the many problems associated with the HIV infection.
- The compound delta-9-tetrahydrocannabinol, which is the active ingredient in marijuana and which was produced chemically as described in U.S. Pat. No. 3,668,224, has been used as an antiemetic to relieve nausea and vomiting in patients receiving cancer chemotherapy.
- A number of cancer investigators have used delta-9-tetrahydrocannabinol to attempt to increase appetite and modify weight loss in cancer patients. For example, in a randomized double-blind crossover study employing oral delta-9-tetrahydrocannabinol and prochlorperazine, 50% of the subjects on delta-9-tetrahydrocannabinol reported an increased food intake while only 29% had a similar response on the prochlorperazine.1 In another study of similar design and using the same medications, patients on delta-9-tetrahydrocannabinol reported feeling more hungry than patients on prochlorperazine.2 Results suggestive of an appetite stimulating effect were also noted by Ekert, et al.3 in groups of children and adolescents 6-19 years of age administered delta-9-tetrahydrocannabinol, prochlorperazine or metaclopramide in crossover design studies.
1 Sallan, S E; Cronin, C; Zelan, M; and Zinberg, N E (Sidney Farber Cancer Institute, Boston, Mass.): Antiemetics in patients receiveing chemotherapy for cancer. A prochlorperazine. N. Engl. J. Med. 301:135-138 (Jan. 17) 1980, No. 3.
2 Ungerleider, J T; Andrysiak, T; Fairbanks, L; Gooodnight, J; Sarna, G; and Jamison, K. (UCLA Center for the Health Sciences, Los Angeles, Calif.): Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636-645 (Aug. 15) 1982, No. 4.
3 Ekert, H; Waters, K D; Jurk, I H; Mobilia, J; and Loughnan, P. (Royal Children's Hospital, Melbourne, Australia): Amerlioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med. J. Aust. 2:657-659 (Dec. 15) 1979.
- In a double blind study, Regelson, et al.4 observed that advanced cancer patients on chemotherapy receiving delta-9-tetrahydrocannabinol maintained their weight better than those
4 Regelson W, Butter J R; Schultz J; Kirk T; Peek L; Green M L; Delta-9-tetrahydrocannabinol, (delta-9-THC) as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. The pharmacology of marihuana, (Braude M C & Szara S eds) Raven Press, N.Y. (1976; pp. 763-766.
- not receiving the delta-9-tetrahydrocannabinol.
- In an open study, Wadleigh, et al.5 observed appetite increases and a lessening of the rate of weight loss in cancer patients.
5 Wadleigh, R; Spaulding, M; Lembersky, B; Zimmer. M: Shepard, K; Plasse, T; Dronabinol enhancement of appetite in cancer patients. Proceedings 1990 American Cancer Society of Clinical Mycology Meeting.
- It is accordingly a primary object of the present invention to provide for the treatment of patients suffering from symptomatic HIV infection so as to improve the appetite and reduce weight loss in such patients.
- Other objects and advantages of the present invention will be apparent from a further reading of the specification and of the appended claims.
- With the above and other objects in view, the present invention mainly comprises the administration to a patient suffering from symptomatic HIV infection of an appetite stimulating effective amount of delta-9-tetrahydrocannabinol.
- The delta-9-tetrahydrocannabinol is preferably administered orally as dronabinol (delta-9-tetrahydrocannabinol in sesame oil-containing capsules). Administration is also possible to achieve the effects of the present invention when the delta-9-tetrahydrocannabinol is in the form of tablets, suppositories, intranasal administration, transdermal administration, inhalants and sublingual administration, as well as administration by injection.
- The dosage range of delta-9-tetrahydrocannabinol may vary widely from 2.5 mg to 20 mg daily, in single or divided doses.
- The following is given to further illustrate the present invention. The scope of the invention is not, however, meant to be limited to the specific details thereof.
- Soft gelatin capsules were filled with delta-9-tetrahydrocannabinol in sesame oil (dronabinol). Capsules were filled with 2.5 mg delta-9-tetrahydrocannabinol per capsule or 5 mg delta-9-tetrahydrocannabinol per capsule.
- Ten symptomatic HIV patients were treated with delta-9-tetrahydrocannabinol. The patients studied were all homosexual males; one had a history of intravenous drug abuse as well. The infectious complications which they had represent the spectrum of those usually seen in a symptomatic HIV-infected population.
- Most of the patients had received or were on antiviral therapy, primarily zidovudine (azidothymidine). Two had previously received and one was receiving megesterol acetate as well. Patients received delta-9-tetrahydrocannabinol as dronabinol (delta-9-tetrahydrocannabinol in sesame oil in soft gelatin capsules), usually at a dose of 2.5 mg, for one to five months. Treatment continued for most of the patients at the time of this analysis. The dose varied. The patients were instructed to take medication up to four times daily as needed; many took it somewhat less often.
- Initially, patients were losing a median of 0.93 kg/mo. On therapy, they gained 0.54 kg/mo. The median difference on versus pre-therapy was 1.92 kg/mo. Seven patients gained weight while two others had a decrease in weight loss. This result was unexpected as previous studies in cancer patients showed that while weight loss lessened, patients rarely gained weight.
- In a prospective, dose-ranging study, 23 patients with symptomatic HIV infection were treated with dronabinol at a dose of 2.5 mg twice daily to 5.0 mg three times daily. Of these, 13 completed approximately one month on therapy. Of those completing one month on therapy, seven gained weight.
- At a dose which appears optimal, seven of eight patients completed one month treatment. At that dose, most patients did not experience side effects. Most of those patients who did experience side effects found them tolerable. Confirming the unexpected results of Example I, five of the seven patients gained weight. The median rate of weight loss prior to therapy was 1.62 kg/mo; on therapy, the median weight gain was 1.56 kg/mo. The median improvement in the rate of weight change was 3.06 kg/mo, or approximately 1.5 lbs/wk.
- It thus appears that delta-9-tetrahydrocannabinol can provide a significant tool in the treatment of patients with symptomatic HIV infection by improving appetite and reducing weight loss.
- While the invention has been illustrated with respect to specific dosages, it is apparent that variations and modifications can be made without departing from the spirit or scope of the invention.
Claims (16)
1. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient, the method comprising orally administering to the patient a pharmaceutical composition comprising dronabinol, wherein the dronabinol is present in the composition in a total amount of about 2.5 mg to about 20 mg.
2. The method of claim 1 , wherein the human patient is male.
3. The method of claim 1 , wherein the weight gain comprises an weight change of approximately 1.5 lbs/week.
4. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient comprising:
providing to the patient delta-9-tetrahydrocannabinol in a dosing regimen optimized to minimize side effects.
5. The method of claim 4 , wherein the weight gain comprises a weight change of approximately 1.5 lbs/week.
6. The method of claim 4 , wherein the side effects comprise nausea.
7. The method of claim 4 , wherein the side effects comprise CNS effects.
8. The method of claim 4 , wherein the human patient is male.
9. The method of claim 1 , wherein the human patient is on antiviral therapy.
10. The method of claim 9 , wherein the anti-viral therapy comprises azidothymidine.
11. The method of claim 9 , wherein the anti-viral therapy comprises megesterol acetate.
12. The method of claim 1 , wherein the human patient had received anti-viral therapy.
13. A method of treating a human patient to stimulate weight gain comprising:
administering to the patient an effective amount of delta-9-tetrahydrocannabinol.
14. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient comprising:
administering to the patient an appetite-stimulating effective amount of delta-9-tetrahydrocannabinol in conjunction with at least one additional medication.
15. The method of claim 14 , wherein said additional medication comprises an antiviral therapy.
16. A method of treating an HIV human patient comprising:
administering an effective amount of delta-9-tetrahydrocannabinol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/537,914 US20070088077A1 (en) | 1991-02-26 | 2006-10-02 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66151491A | 1991-02-26 | 1991-02-26 | |
US07/893,554 US6703418B2 (en) | 1991-02-26 | 1992-06-03 | Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection |
US10/735,017 US20040209944A1 (en) | 1991-02-26 | 2003-12-12 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection |
US11/537,914 US20070088077A1 (en) | 1991-02-26 | 2006-10-02 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/735,017 Continuation US20040209944A1 (en) | 1991-02-26 | 2003-12-12 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070088077A1 true US20070088077A1 (en) | 2007-04-19 |
Family
ID=24653916
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/893,554 Expired - Lifetime US6703418B2 (en) | 1991-02-26 | 1992-06-03 | Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection |
US10/735,017 Abandoned US20040209944A1 (en) | 1991-02-26 | 2003-12-12 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection |
US11/537,914 Abandoned US20070088077A1 (en) | 1991-02-26 | 2006-10-02 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/893,554 Expired - Lifetime US6703418B2 (en) | 1991-02-26 | 1992-06-03 | Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection |
US10/735,017 Abandoned US20040209944A1 (en) | 1991-02-26 | 2003-12-12 | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection |
Country Status (1)
Country | Link |
---|---|
US (3) | US6703418B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160888A1 (en) * | 2004-12-09 | 2006-07-20 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
US20080112895A1 (en) * | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
US20090181080A1 (en) * | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007510736A (en) * | 2003-11-05 | 2007-04-26 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis |
TWI369203B (en) * | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
US20060258738A1 (en) * | 2005-05-12 | 2006-11-16 | Douglas Dieterich | Use of dronabinol for treatment of side effects of Hepatitis C therapy |
TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
WO2007032962A2 (en) * | 2005-09-09 | 2007-03-22 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
US20130281523A1 (en) * | 2010-11-18 | 2013-10-24 | Peter LETENDRE | Low dose cannabinoid medicaments |
EP2654864B1 (en) | 2010-12-22 | 2020-10-28 | Syqe Medical Ltd. | System for drug delivery |
CA2952934A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
DK3160558T3 (en) | 2014-06-30 | 2020-04-27 | Syqe Medical Ltd | FLOW CONTROL INHALING DEVICE |
AU2015283590B2 (en) | 2014-06-30 | 2020-04-16 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
KR102561375B1 (en) | 2014-06-30 | 2023-08-01 | 사이키 메디컬 엘티디. | Clamping chamber for clamping inhaler dose cartridge |
ES2898173T3 (en) | 2014-06-30 | 2022-03-04 | Syqe Medical Ltd | Devices and systems for the pulmonary administration of active ingredients |
BR112016030944B1 (en) | 2014-06-30 | 2022-03-15 | Syqe Medical Ltd | Method for administering an active agent to a user |
US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
US10028904B2 (en) | 2014-12-04 | 2018-07-24 | Wisconsin Alumni Research Foundation | Transdermal cannabinoid formulations |
BR102015024165A2 (en) * | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | oral pharmaceutical composition comprising cannabinoid, process for its preparation and use |
EP3399972B1 (en) | 2016-01-06 | 2021-03-31 | Syqe Medical Ltd. | Low dose therapeutic treatment |
WO2018080933A1 (en) * | 2016-10-24 | 2018-05-03 | Pellficure Pharmaceuticals Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
Citations (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
US6292678B1 (en) * | 1999-05-13 | 2001-09-18 | Stereotaxis, Inc. | Method of magnetically navigating medical devices with magnetic fields and gradients, and medical devices adapted therefor |
US6296604B1 (en) * | 1999-03-17 | 2001-10-02 | Stereotaxis, Inc. | Methods of and compositions for treating vascular defects |
US6304768B1 (en) * | 1997-11-12 | 2001-10-16 | Stereotaxis, Inc. | Method and apparatus using shaped field of repositionable magnet to guide implant |
US20010038683A1 (en) * | 1998-11-03 | 2001-11-08 | Ritter Rogers C. | Open field system for magnetic surgery |
US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
US6330467B1 (en) * | 1999-02-04 | 2001-12-11 | Stereotaxis, Inc. | Efficient magnet system for magnetically-assisted surgery |
US20020019644A1 (en) * | 1999-07-12 | 2002-02-14 | Hastings Roger N. | Magnetically guided atherectomy |
US6352363B1 (en) * | 2001-01-16 | 2002-03-05 | Stereotaxis, Inc. | Shielded x-ray source, method of shielding an x-ray source, and magnetic surgical system with shielded x-ray source |
US6375606B1 (en) * | 1999-03-17 | 2002-04-23 | Stereotaxis, Inc. | Methods of and apparatus for treating vascular defects |
US6385472B1 (en) * | 1999-09-10 | 2002-05-07 | Stereotaxis, Inc. | Magnetically navigable telescoping catheter and method of navigating telescoping catheter |
US6401723B1 (en) * | 2000-02-16 | 2002-06-11 | Stereotaxis, Inc. | Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments |
US6428551B1 (en) * | 1999-03-30 | 2002-08-06 | Stereotaxis, Inc. | Magnetically navigable and/or controllable device for removing material from body lumens and cavities |
US6459924B1 (en) * | 1997-11-12 | 2002-10-01 | Stereotaxis, Inc. | Articulated magnetic guidance systems and devices and methods for using same for magnetically-assisted surgery |
US20020177789A1 (en) * | 2001-05-06 | 2002-11-28 | Ferry Steven J. | System and methods for advancing a catheter |
US6505062B1 (en) * | 1998-02-09 | 2003-01-07 | Stereotaxis, Inc. | Method for locating magnetic implant by source field |
US6522909B1 (en) * | 1998-08-07 | 2003-02-18 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling catheters in body lumens and cavities |
US6524303B1 (en) * | 2000-09-08 | 2003-02-25 | Stereotaxis, Inc. | Variable stiffness magnetic catheter |
US6537196B1 (en) * | 2000-10-24 | 2003-03-25 | Stereotaxis, Inc. | Magnet assembly with variable field directions and methods of magnetically navigating medical objects |
US6562019B1 (en) * | 1999-09-20 | 2003-05-13 | Stereotaxis, Inc. | Method of utilizing a magnetically guided myocardial treatment system |
US6662034B2 (en) * | 2000-11-15 | 2003-12-09 | Stereotaxis, Inc. | Magnetically guidable electrophysiology catheter |
US6677752B1 (en) * | 2000-11-20 | 2004-01-13 | Stereotaxis, Inc. | Close-in shielding system for magnetic medical treatment instruments |
US20040019447A1 (en) * | 2002-07-16 | 2004-01-29 | Yehoshua Shachar | Apparatus and method for catheter guidance control and imaging |
US6702804B1 (en) * | 1999-10-04 | 2004-03-09 | Stereotaxis, Inc. | Method for safely and efficiently navigating magnetic devices in the body |
US20040068173A1 (en) * | 2002-08-06 | 2004-04-08 | Viswanathan Raju R. | Remote control of medical devices using a virtual device interface |
US6733511B2 (en) * | 1998-10-02 | 2004-05-11 | Stereotaxis, Inc. | Magnetically navigable and/or controllable device for removing material from body lumens and cavities |
US20040096511A1 (en) * | 2002-07-03 | 2004-05-20 | Jonathan Harburn | Magnetically guidable carriers and methods for the targeted magnetic delivery of substances in the body |
US20040133130A1 (en) * | 2003-01-06 | 2004-07-08 | Ferry Steven J. | Magnetically navigable medical guidewire |
US20040157082A1 (en) * | 2002-07-22 | 2004-08-12 | Ritter Rogers C. | Coated magnetically responsive particles, and embolic materials using coated magnetically responsive particles |
US20040158972A1 (en) * | 2002-11-07 | 2004-08-19 | Creighton Francis M. | Method of making a compound magnet |
US20040186376A1 (en) * | 2002-09-30 | 2004-09-23 | Hogg Bevil J. | Method and apparatus for improved surgical navigation employing electronic identification with automatically actuated flexible medical devices |
US6817364B2 (en) * | 2000-07-24 | 2004-11-16 | Stereotaxis, Inc. | Magnetically navigated pacing leads, and methods for delivering medical devices |
US20040249263A1 (en) * | 2003-03-13 | 2004-12-09 | Creighton Francis M. | Magnetic navigation system and magnet system therefor |
US20040249262A1 (en) * | 2003-03-13 | 2004-12-09 | Werp Peter R. | Magnetic navigation system |
US6834201B2 (en) * | 2001-01-29 | 2004-12-21 | Stereotaxis, Inc. | Catheter navigation within an MR imaging device |
US20040260172A1 (en) * | 2003-04-24 | 2004-12-23 | Ritter Rogers C. | Magnetic navigation of medical devices in magnetic fields |
US20050020911A1 (en) * | 2002-04-10 | 2005-01-27 | Viswanathan Raju R. | Efficient closed loop feedback navigation |
US20050043611A1 (en) * | 2003-05-02 | 2005-02-24 | Sabo Michael E. | Variable magnetic moment MR navigation |
US20050065435A1 (en) * | 2003-07-22 | 2005-03-24 | John Rauch | User interface for remote control of medical devices |
US20050096589A1 (en) * | 2003-10-20 | 2005-05-05 | Yehoshua Shachar | System and method for radar-assisted catheter guidance and control |
US20050113812A1 (en) * | 2003-09-16 | 2005-05-26 | Viswanathan Raju R. | User interface for remote control of medical devices |
US20050113628A1 (en) * | 2002-01-23 | 2005-05-26 | Creighton Francis M.Iv | Rotating and pivoting magnet for magnetic navigation |
US20050119687A1 (en) * | 2003-09-08 | 2005-06-02 | Dacey Ralph G.Jr. | Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels |
US6902528B1 (en) * | 1999-04-14 | 2005-06-07 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling endoscopes in body lumens and cavities |
US20050182315A1 (en) * | 2003-11-07 | 2005-08-18 | Ritter Rogers C. | Magnetic resonance imaging and magnetic navigation systems and methods |
US20050256398A1 (en) * | 2004-05-12 | 2005-11-17 | Hastings Roger N | Systems and methods for interventional medicine |
US6968846B2 (en) * | 2002-03-07 | 2005-11-29 | Stereotaxis, Inc. | Method and apparatus for refinably accurate localization of devices and instruments in scattering environments |
US6975197B2 (en) * | 2002-01-23 | 2005-12-13 | Stereotaxis, Inc. | Rotating and pivoting magnet for magnetic navigation |
US6980843B2 (en) * | 2003-05-21 | 2005-12-27 | Stereotaxis, Inc. | Electrophysiology catheter |
US20060009735A1 (en) * | 2004-06-29 | 2006-01-12 | Viswanathan Raju R | Navigation of remotely actuable medical device using control variable and length |
US20060025679A1 (en) * | 2004-06-04 | 2006-02-02 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060036163A1 (en) * | 2004-07-19 | 2006-02-16 | Viswanathan Raju R | Method of, and apparatus for, controlling medical navigation systems |
US20060041245A1 (en) * | 2001-05-06 | 2006-02-23 | Ferry Steven J | Systems and methods for medical device a dvancement and rotation |
US7008418B2 (en) * | 2002-05-09 | 2006-03-07 | Stereotaxis, Inc. | Magnetically assisted pulmonary vein isolation |
US20060058646A1 (en) * | 2004-08-26 | 2006-03-16 | Raju Viswanathan | Method for surgical navigation utilizing scale-invariant registration between a navigation system and a localization system |
US7019610B2 (en) * | 2002-01-23 | 2006-03-28 | Stereotaxis, Inc. | Magnetic navigation system |
US7020512B2 (en) * | 2002-01-14 | 2006-03-28 | Stereotaxis, Inc. | Method of localizing medical devices |
US20060074297A1 (en) * | 2004-08-24 | 2006-04-06 | Viswanathan Raju R | Methods and apparatus for steering medical devices in body lumens |
US20060079812A1 (en) * | 2004-09-07 | 2006-04-13 | Viswanathan Raju R | Magnetic guidewire for lesion crossing |
US20060079745A1 (en) * | 2004-10-07 | 2006-04-13 | Viswanathan Raju R | Surgical navigation with overlay on anatomical images |
US20060093193A1 (en) * | 2004-10-29 | 2006-05-04 | Viswanathan Raju R | Image-based medical device localization |
US20060094956A1 (en) * | 2004-10-29 | 2006-05-04 | Viswanathan Raju R | Restricted navigation controller for, and methods of controlling, a remote navigation system |
US20060100505A1 (en) * | 2004-10-26 | 2006-05-11 | Viswanathan Raju R | Surgical navigation using a three-dimensional user interface |
US7066924B1 (en) * | 1997-11-12 | 2006-06-27 | Stereotaxis, Inc. | Method of and apparatus for navigating medical devices in body lumens by a guide wire with a magnetic tip |
US20060144408A1 (en) * | 2004-07-23 | 2006-07-06 | Ferry Steven J | Micro-catheter device and method of using same |
US20060144407A1 (en) * | 2004-07-20 | 2006-07-06 | Anthony Aliberto | Magnetic navigation manipulation apparatus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5055446A (en) * | 1988-10-21 | 1991-10-08 | University Of Cincinnati | Method to improve survival of patients during sepsis by diet composition |
NZ333399A (en) * | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
-
1992
- 1992-06-03 US US07/893,554 patent/US6703418B2/en not_active Expired - Lifetime
-
2003
- 2003-12-12 US US10/735,017 patent/US20040209944A1/en not_active Abandoned
-
2006
- 2006-10-02 US US11/537,914 patent/US20070088077A1/en not_active Abandoned
Patent Citations (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
US6304768B1 (en) * | 1997-11-12 | 2001-10-16 | Stereotaxis, Inc. | Method and apparatus using shaped field of repositionable magnet to guide implant |
US6507751B2 (en) * | 1997-11-12 | 2003-01-14 | Stereotaxis, Inc. | Method and apparatus using shaped field of repositionable magnet to guide implant |
US7066924B1 (en) * | 1997-11-12 | 2006-06-27 | Stereotaxis, Inc. | Method of and apparatus for navigating medical devices in body lumens by a guide wire with a magnetic tip |
US6459924B1 (en) * | 1997-11-12 | 2002-10-01 | Stereotaxis, Inc. | Articulated magnetic guidance systems and devices and methods for using same for magnetically-assisted surgery |
US7010338B2 (en) * | 1998-02-09 | 2006-03-07 | Stereotaxis, Inc. | Device for locating magnetic implant by source field |
US6505062B1 (en) * | 1998-02-09 | 2003-01-07 | Stereotaxis, Inc. | Method for locating magnetic implant by source field |
US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
US6522909B1 (en) * | 1998-08-07 | 2003-02-18 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling catheters in body lumens and cavities |
US6733511B2 (en) * | 1998-10-02 | 2004-05-11 | Stereotaxis, Inc. | Magnetically navigable and/or controllable device for removing material from body lumens and cavities |
US20010038683A1 (en) * | 1998-11-03 | 2001-11-08 | Ritter Rogers C. | Open field system for magnetic surgery |
US20040064153A1 (en) * | 1999-02-04 | 2004-04-01 | Creighton Francis M. | Efficient magnet system for magnetically-assisted surgery |
US6630879B1 (en) * | 1999-02-04 | 2003-10-07 | Stereotaxis, Inc. | Efficient magnet system for magnetically-assisted surgery |
US6330467B1 (en) * | 1999-02-04 | 2001-12-11 | Stereotaxis, Inc. | Efficient magnet system for magnetically-assisted surgery |
US6375606B1 (en) * | 1999-03-17 | 2002-04-23 | Stereotaxis, Inc. | Methods of and apparatus for treating vascular defects |
US6364823B1 (en) * | 1999-03-17 | 2002-04-02 | Stereotaxis, Inc. | Methods of and compositions for treating vascular defects |
US6296604B1 (en) * | 1999-03-17 | 2001-10-02 | Stereotaxis, Inc. | Methods of and compositions for treating vascular defects |
US6428551B1 (en) * | 1999-03-30 | 2002-08-06 | Stereotaxis, Inc. | Magnetically navigable and/or controllable device for removing material from body lumens and cavities |
US6902528B1 (en) * | 1999-04-14 | 2005-06-07 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling endoscopes in body lumens and cavities |
US6292678B1 (en) * | 1999-05-13 | 2001-09-18 | Stereotaxis, Inc. | Method of magnetically navigating medical devices with magnetic fields and gradients, and medical devices adapted therefor |
US20020019644A1 (en) * | 1999-07-12 | 2002-02-14 | Hastings Roger N. | Magnetically guided atherectomy |
US6911026B1 (en) * | 1999-07-12 | 2005-06-28 | Stereotaxis, Inc. | Magnetically guided atherectomy |
US6385472B1 (en) * | 1999-09-10 | 2002-05-07 | Stereotaxis, Inc. | Magnetically navigable telescoping catheter and method of navigating telescoping catheter |
US20040006301A1 (en) * | 1999-09-20 | 2004-01-08 | Sell Jonathan C. | Magnetically guided myocardial treatment system |
US6562019B1 (en) * | 1999-09-20 | 2003-05-13 | Stereotaxis, Inc. | Method of utilizing a magnetically guided myocardial treatment system |
US6755816B2 (en) * | 1999-10-04 | 2004-06-29 | Stereotaxis, Inc. | Method for safely and efficiently navigating magnetic devices in the body |
US20040199074A1 (en) * | 1999-10-04 | 2004-10-07 | Ritter Rogers C. | Method for safely and efficiently navigating magnetic devices in the body |
US6702804B1 (en) * | 1999-10-04 | 2004-03-09 | Stereotaxis, Inc. | Method for safely and efficiently navigating magnetic devices in the body |
US6401723B1 (en) * | 2000-02-16 | 2002-06-11 | Stereotaxis, Inc. | Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments |
US6817364B2 (en) * | 2000-07-24 | 2004-11-16 | Stereotaxis, Inc. | Magnetically navigated pacing leads, and methods for delivering medical devices |
US6524303B1 (en) * | 2000-09-08 | 2003-02-25 | Stereotaxis, Inc. | Variable stiffness magnetic catheter |
US6537196B1 (en) * | 2000-10-24 | 2003-03-25 | Stereotaxis, Inc. | Magnet assembly with variable field directions and methods of magnetically navigating medical objects |
US6662034B2 (en) * | 2000-11-15 | 2003-12-09 | Stereotaxis, Inc. | Magnetically guidable electrophysiology catheter |
US6677752B1 (en) * | 2000-11-20 | 2004-01-13 | Stereotaxis, Inc. | Close-in shielding system for magnetic medical treatment instruments |
US6352363B1 (en) * | 2001-01-16 | 2002-03-05 | Stereotaxis, Inc. | Shielded x-ray source, method of shielding an x-ray source, and magnetic surgical system with shielded x-ray source |
US6834201B2 (en) * | 2001-01-29 | 2004-12-21 | Stereotaxis, Inc. | Catheter navigation within an MR imaging device |
US20020177789A1 (en) * | 2001-05-06 | 2002-11-28 | Ferry Steven J. | System and methods for advancing a catheter |
US20060041245A1 (en) * | 2001-05-06 | 2006-02-23 | Ferry Steven J | Systems and methods for medical device a dvancement and rotation |
US7020512B2 (en) * | 2002-01-14 | 2006-03-28 | Stereotaxis, Inc. | Method of localizing medical devices |
US7019610B2 (en) * | 2002-01-23 | 2006-03-28 | Stereotaxis, Inc. | Magnetic navigation system |
US6975197B2 (en) * | 2002-01-23 | 2005-12-13 | Stereotaxis, Inc. | Rotating and pivoting magnet for magnetic navigation |
US20050113628A1 (en) * | 2002-01-23 | 2005-05-26 | Creighton Francis M.Iv | Rotating and pivoting magnet for magnetic navigation |
US6968846B2 (en) * | 2002-03-07 | 2005-11-29 | Stereotaxis, Inc. | Method and apparatus for refinably accurate localization of devices and instruments in scattering environments |
US20050020911A1 (en) * | 2002-04-10 | 2005-01-27 | Viswanathan Raju R. | Efficient closed loop feedback navigation |
US7008418B2 (en) * | 2002-05-09 | 2006-03-07 | Stereotaxis, Inc. | Magnetically assisted pulmonary vein isolation |
US20040096511A1 (en) * | 2002-07-03 | 2004-05-20 | Jonathan Harburn | Magnetically guidable carriers and methods for the targeted magnetic delivery of substances in the body |
US20060116633A1 (en) * | 2002-07-16 | 2006-06-01 | Yehoshua Shachar | System and method for a magnetic catheter tip |
US20060114088A1 (en) * | 2002-07-16 | 2006-06-01 | Yehoshua Shachar | Apparatus and method for generating a magnetic field |
US20040019447A1 (en) * | 2002-07-16 | 2004-01-29 | Yehoshua Shachar | Apparatus and method for catheter guidance control and imaging |
US20040157082A1 (en) * | 2002-07-22 | 2004-08-12 | Ritter Rogers C. | Coated magnetically responsive particles, and embolic materials using coated magnetically responsive particles |
US20040068173A1 (en) * | 2002-08-06 | 2004-04-08 | Viswanathan Raju R. | Remote control of medical devices using a virtual device interface |
US20040186376A1 (en) * | 2002-09-30 | 2004-09-23 | Hogg Bevil J. | Method and apparatus for improved surgical navigation employing electronic identification with automatically actuated flexible medical devices |
US20040158972A1 (en) * | 2002-11-07 | 2004-08-19 | Creighton Francis M. | Method of making a compound magnet |
US20040133130A1 (en) * | 2003-01-06 | 2004-07-08 | Ferry Steven J. | Magnetically navigable medical guidewire |
US20040249263A1 (en) * | 2003-03-13 | 2004-12-09 | Creighton Francis M. | Magnetic navigation system and magnet system therefor |
US20040249262A1 (en) * | 2003-03-13 | 2004-12-09 | Werp Peter R. | Magnetic navigation system |
US20040260172A1 (en) * | 2003-04-24 | 2004-12-23 | Ritter Rogers C. | Magnetic navigation of medical devices in magnetic fields |
US20050043611A1 (en) * | 2003-05-02 | 2005-02-24 | Sabo Michael E. | Variable magnetic moment MR navigation |
US6980843B2 (en) * | 2003-05-21 | 2005-12-27 | Stereotaxis, Inc. | Electrophysiology catheter |
US20050065435A1 (en) * | 2003-07-22 | 2005-03-24 | John Rauch | User interface for remote control of medical devices |
US20050119687A1 (en) * | 2003-09-08 | 2005-06-02 | Dacey Ralph G.Jr. | Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels |
US20050113812A1 (en) * | 2003-09-16 | 2005-05-26 | Viswanathan Raju R. | User interface for remote control of medical devices |
US20050096589A1 (en) * | 2003-10-20 | 2005-05-05 | Yehoshua Shachar | System and method for radar-assisted catheter guidance and control |
US20050182315A1 (en) * | 2003-11-07 | 2005-08-18 | Ritter Rogers C. | Magnetic resonance imaging and magnetic navigation systems and methods |
US20050256398A1 (en) * | 2004-05-12 | 2005-11-17 | Hastings Roger N | Systems and methods for interventional medicine |
US20060041181A1 (en) * | 2004-06-04 | 2006-02-23 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060025679A1 (en) * | 2004-06-04 | 2006-02-02 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060041179A1 (en) * | 2004-06-04 | 2006-02-23 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060041178A1 (en) * | 2004-06-04 | 2006-02-23 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060041180A1 (en) * | 2004-06-04 | 2006-02-23 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060036125A1 (en) * | 2004-06-04 | 2006-02-16 | Viswanathan Raju R | User interface for remote control of medical devices |
US20060009735A1 (en) * | 2004-06-29 | 2006-01-12 | Viswanathan Raju R | Navigation of remotely actuable medical device using control variable and length |
US20060036163A1 (en) * | 2004-07-19 | 2006-02-16 | Viswanathan Raju R | Method of, and apparatus for, controlling medical navigation systems |
US20060144407A1 (en) * | 2004-07-20 | 2006-07-06 | Anthony Aliberto | Magnetic navigation manipulation apparatus |
US20060144408A1 (en) * | 2004-07-23 | 2006-07-06 | Ferry Steven J | Micro-catheter device and method of using same |
US20060074297A1 (en) * | 2004-08-24 | 2006-04-06 | Viswanathan Raju R | Methods and apparatus for steering medical devices in body lumens |
US20060058646A1 (en) * | 2004-08-26 | 2006-03-16 | Raju Viswanathan | Method for surgical navigation utilizing scale-invariant registration between a navigation system and a localization system |
US20060079812A1 (en) * | 2004-09-07 | 2006-04-13 | Viswanathan Raju R | Magnetic guidewire for lesion crossing |
US20060079745A1 (en) * | 2004-10-07 | 2006-04-13 | Viswanathan Raju R | Surgical navigation with overlay on anatomical images |
US20060100505A1 (en) * | 2004-10-26 | 2006-05-11 | Viswanathan Raju R | Surgical navigation using a three-dimensional user interface |
US20060093193A1 (en) * | 2004-10-29 | 2006-05-04 | Viswanathan Raju R | Image-based medical device localization |
US20060094956A1 (en) * | 2004-10-29 | 2006-05-04 | Viswanathan Raju R | Restricted navigation controller for, and methods of controlling, a remote navigation system |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060160888A1 (en) * | 2004-12-09 | 2006-07-20 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
US8628796B2 (en) | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
US20080112895A1 (en) * | 2006-08-04 | 2008-05-15 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
US20090181080A1 (en) * | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
Also Published As
Publication number | Publication date |
---|---|
US20030100602A1 (en) | 2003-05-29 |
US6703418B2 (en) | 2004-03-09 |
US20040209944A1 (en) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070088077A1 (en) | Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection | |
Kligler et al. | Peppermint oil | |
US5498631A (en) | Method for treatment of menopausal and premenstrual symptoms | |
RU2002127804A (en) | MEDICINAL SYSTEM FOR TREATMENT OF COMPLICATIONS CONNECTED WITH DIABETES AND NEUROPATHY, AND THEIR APPLICATION | |
CA2386215C (en) | Method for treatment of chronic venous insufficiencies using an extract of red vine leaves | |
US6248307B1 (en) | Compositions and treatment for alleviation of symptoms associated with menopause | |
EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
EP0654271B1 (en) | Pharmaceutical composition for treating aids | |
KR19980701720A (en) | Combination medicine for the treatment of migraine and other diseases containing sesquiterpene lactones and vitamin B complex | |
US4833154A (en) | Natural sleeping pill to prevent and alleviate insomnia | |
JP2943247B2 (en) | Hypnosis / Sedative | |
KR100420673B1 (en) | Nasal administration to treat delayed nausea | |
IE904084A1 (en) | Treatment of depression | |
EP1476160B1 (en) | Pharmaceutical combination of artesunate and mefloquine for therapy of malaria | |
HEIM et al. | Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy‐induced nausea and vomiting | |
CASSILETH et al. | Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia | |
US4265887A (en) | Composition and method for treatment of hemorrhoids | |
Glass | Treatment of rattlesnake bites | |
AU2001228790B2 (en) | A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enthalt | |
GB2129299A (en) | Pharmaceutical compositions | |
Petry et al. | Medicinal herbs: answers and advice, part 1 | |
DAVIS | Thiabendazole in Pinworm Infestations: II. Comparison of Single and Intermittent Therapy, Long-Term Follow-Up, and Evaluation of New Dosage Form | |
KR960014873B1 (en) | Pharmaceutical compositions for alleviation of panic disorders containing gepirone | |
Berk, Lionel, Bauer, John L. & Castle | Folic acid: A report of 12 patients treated with synthetic pteroylglutamic acid: With comments on the pertinent literature | |
US5081129A (en) | Method of treatment of anemia with seratonin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIMED PHARMACEUTICALS, LLC, GEORGIA Free format text: CHANGE OF NAME;ASSIGNOR:UNIMED PHARMACEUTICALS, INC.;REEL/FRAME:020654/0154 Effective date: 20071228 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |